AZD-2115
- Generic Name
- AZD-2115
PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT03097380
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients
Phase 2
Completed
- Conditions
- COPD
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT01498081
- Locations
- 🇸🇪
Research Site, Lund, Sweden
AZD2115 Multiple Ascending Dose Study
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT01445782
- Locations
- 🇬🇧
Research Site, London, UK, United Kingdom
AZD2115 Single Ascending Dose Study
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary DiseaseLung Disease Causing Persistent Narrowing of the Airways
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2011-08-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 96
- Registration Number
- NCT01283984
- Locations
- 🇬🇧
Research Site, London, UK, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath